NASDAQ:AVBP ArriVent BioPharma (AVBP) Stock Price, News & Analysis $28.01 +1.41 (+5.30%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$26.24▼$28.2450-Day Range$17.93▼$28.0152-Week Range$14.35▼$28.65Volume392,304 shsAverage Volume135,515 shsMarket Capitalization$938.17 millionP/E RatioN/ADividend YieldN/APrice Target$31.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get ArriVent BioPharma alerts: Email Address ArriVent BioPharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside12.1% Upside$31.40 Price TargetShort InterestBearish8.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.36Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.03) to ($3.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.20 out of 5 starsMedical Sector888th out of 910 stocksPharmaceutical Preparations Industry416th out of 426 stocks 2.5 Analyst's Opinion Consensus RatingArriVent BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArriVent BioPharma has only been the subject of 2 research reports in the past 90 days.Read more about ArriVent BioPharma's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.41% of the float of ArriVent BioPharma has been sold short.Short Interest Ratio / Days to CoverArriVent BioPharma has a short interest ratio ("days to cover") of 19.3, which indicates bearish sentiment.Change versus previous monthShort interest in ArriVent BioPharma has recently decreased by 2.40%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArriVent BioPharma does not currently pay a dividend.Dividend GrowthArriVent BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVBP. Previous Next 1.5 News and Social Media Coverage News SentimentArriVent BioPharma has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ArriVent BioPharma this week, compared to 2 articles on an average week.Search Interest1 people have searched for AVBP on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 9.48% of the stock of ArriVent BioPharma is held by institutions.Read more about ArriVent BioPharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ArriVent BioPharma are expected to decrease in the coming year, from ($3.03) to ($3.20) per share.Price to Book Value per Share RatioArriVent BioPharma has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ArriVent BioPharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About ArriVent BioPharma Stock (NASDAQ:AVBP)ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Read More AVBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVBP Stock News HeadlinesSeptember 6 at 7:55 PM | finance.yahoo.comWe're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn RateAugust 26, 2024 | markets.businessinsider.comArriVent BioPharma’s Firmonertinib: A Promising Treatment for EGFR PACC Mutations in NSCLCSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 19, 2024 | msn.comHere's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price StrengthAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for ArriVent BioPharma on Strong Clinical Prospects and Financial StabilityAugust 16, 2024 | msn.comArriVent BioPharma Reports Strong Second Quarter and Highlights ProgressAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed on ArriVent BioPharma’s Strong Clinical Developments and Strategic PartnershipsAugust 15, 2024 | finanznachrichten.deArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2024 Financial ResultsSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 15, 2024 | businesswire.comAarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharmaAugust 14, 2024 | globenewswire.comArriVent BioPharma Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | msn.comArriVent BioPharma to Present Groundbreaking Data at 2024 World Conference on Lung CancerAugust 12, 2024 | globenewswire.comArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung CancerJuly 27, 2024 | finance.yahoo.comArriVent BioPharma, Inc. (NASDAQ:AVBP) institutional investors have had a good week as stock gains 19%July 23, 2024 | msn.comOppenheimer starts ArriVent BioPharma at outperformJune 5, 2024 | globenewswire.comArriVent Announces a Multi-Target ADC Collaboration with AlphamabMay 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for ArriVent BioPharma on Strong Drug Trial Prospects and Strategic AdvancementsMay 16, 2024 | globenewswire.comArriVent Appoints John Hohneker, M.D., to its Board of DirectorsSee More Headlines Receive AVBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVBP Previous SymbolNASDAQ:AVBP CUSIPN/A CIK1868279 Webwww.arrivent.com Phone628-277-4836FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$31.40 High Stock Price Target$35.00 Low Stock Price Target$27.00 Potential Upside/Downside+12.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio25.50 Quick Ratio25.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.83 per share Price / Book3.17Miscellaneous Outstanding Shares33,494,000Free FloatN/AMarket Cap$938.17 million OptionableN/A BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Zhengbin Yao Ph.D. (Age 58)Co-Founder, Chairman, President & CEO Comp: $791.09kDr. Stuart Lutzker M.D. (Age 63)Ph.D., Co-Founder, President of Research & Development and Director Comp: $709.43kMs. Robin LaChapelle M.A. (Age 51)Co-Founder & COO Comp: $586.45kMr. Winston Kung M.B.A. (Age 48)CFO & Treasurer Ms. Yang Wang Ph.D.Chief Technology OfficerMr. James Paul Kastenmayer J.D. (Age 52)Ph.D., General Counsel & Secretary Dr. Dandan Dong (Age 39)Chief Business Officer Ms. Meghna ChowdarySenior Vice President of Commercial StrategyMore ExecutivesKey CompetitorsTG TherapeuticsNASDAQ:TGTXBiohavenNYSE:BHVNHUTCHMEDNASDAQ:HCMXenon PharmaceuticalsNASDAQ:XENESpringWorks TherapeuticsNASDAQ:SWTXView All CompetitorsInsiders & InstitutionsNovo Holdings A SBought 422,860 shares on 8/20/2024Ownership: 4.478%Rhumbline AdvisersBought 2,942 shares on 8/1/2024Ownership: 0.038%AlphaCentric Advisors LLCBought 3,000 shares on 7/26/2024Ownership: 0.257%Bank of New York Mellon CorpBought 7,140 shares on 7/26/2024Ownership: 0.089%Hillhouse Investment ManagemenBought 555,555 shares on 1/30/2024Total: $10.00 M ($18.00/share)View All Insider TransactionsView All Institutional Transactions AVBP Stock Analysis - Frequently Asked Questions How have AVBP shares performed this year? ArriVent BioPharma's stock was trading at $20.00 at the start of the year. Since then, AVBP stock has increased by 40.1% and is now trading at $28.01. View the best growth stocks for 2024 here. How were ArriVent BioPharma's earnings last quarter? ArriVent BioPharma, Inc. (NASDAQ:AVBP) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.65). When did ArriVent BioPharma IPO? ArriVent BioPharma (AVBP) raised $175 million in an IPO on Friday, January 26th 2024. The company issued 9,722,222 shares at $18.00 per share. When did ArriVent BioPharma's lock-up period expire? ArriVent BioPharma's lock-up period expired on Wednesday, July 24th. ArriVent BioPharma had issued 9,722,222 shares in its initial public offering on January 26th. The total size of the offering was $174,999,996 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period. Who are ArriVent BioPharma's major shareholders? Top institutional investors of ArriVent BioPharma include Novo Holdings A S (4.48%), AlphaCentric Advisors LLC (0.26%), Bank of New York Mellon Corp (0.09%) and Rhumbline Advisers (0.04%). Insiders that own company stock include Hillhouse Investment Managemen and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of ArriVent BioPharma? Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVBP) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
